Rathbones Group PLC Sells 245 Shares of Axon Enterprise, Inc. (NASDAQ:AXON)

Rathbones Group PLC lowered its stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by 0.9% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 27,495 shares of the biotechnology company’s stock after selling 245 shares during the period. Rathbones Group PLC’s holdings in Axon Enterprise were worth $8,090,000 as of its most recent filing with the SEC.

Several other institutional investors also recently added to or reduced their stakes in the stock. Plato Investment Management Ltd bought a new position in Axon Enterprise during the second quarter valued at about $529,000. Thompson Siegel & Walmsley LLC bought a new position in Axon Enterprise during the second quarter valued at about $273,000. J.W. Cole Advisors Inc. bought a new position in Axon Enterprise during the second quarter valued at about $366,000. OV Management LLC grew its position in Axon Enterprise by 27.1% during the second quarter. OV Management LLC now owns 3,367 shares of the biotechnology company’s stock valued at $991,000 after buying an additional 717 shares during the period. Finally, Envestnet Asset Management Inc. grew its position in Axon Enterprise by 12.0% during the second quarter. Envestnet Asset Management Inc. now owns 79,908 shares of the biotechnology company’s stock valued at $23,512,000 after buying an additional 8,575 shares during the period. Institutional investors own 79.08% of the company’s stock.

Insider Activity at Axon Enterprise

In related news, Director Matthew R. Mcbrady sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, August 9th. The shares were sold at an average price of $364.66, for a total value of $729,320.00. Following the sale, the director now directly owns 4,892 shares of the company’s stock, valued at $1,783,916.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Matthew R. Mcbrady sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, August 9th. The shares were sold at an average price of $364.66, for a total value of $729,320.00. Following the sale, the director now directly owns 4,892 shares of the company’s stock, valued at $1,783,916.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, President Joshua Isner sold 25,811 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $359.84, for a total transaction of $9,287,830.24. Following the completion of the sale, the president now directly owns 228,166 shares in the company, valued at $82,103,253.44. The disclosure for this sale can be found here. Insiders have sold 316,981 shares of company stock valued at $115,281,744 over the last three months. 6.10% of the stock is owned by corporate insiders.

Axon Enterprise Trading Down 1.3 %

Shares of Axon Enterprise stock opened at $379.61 on Monday. Axon Enterprise, Inc. has a 12-month low of $189.12 and a 12-month high of $385.00. The company has a market cap of $28.69 billion, a price-to-earnings ratio of 111.00, a PEG ratio of 10.30 and a beta of 0.94. The company has a current ratio of 2.88, a quick ratio of 2.52 and a debt-to-equity ratio of 0.35. The company’s 50-day moving average price is $338.92 and its 200-day moving average price is $314.68.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.18. The firm had revenue of $504.00 million for the quarter, compared to the consensus estimate of $478.35 million. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. The company’s revenue for the quarter was up 34.5% on a year-over-year basis. During the same period in the prior year, the firm posted $0.80 earnings per share. On average, equities analysts expect that Axon Enterprise, Inc. will post 1.79 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Craig Hallum increased their price target on shares of Axon Enterprise from $370.00 to $376.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Needham & Company LLC reiterated a “buy” rating and set a $400.00 target price on shares of Axon Enterprise in a research report on Wednesday, August 7th. Bank of America started coverage on shares of Axon Enterprise in a research report on Wednesday, July 17th. They set a “buy” rating and a $380.00 target price for the company. Jefferies Financial Group started coverage on shares of Axon Enterprise in a research report on Wednesday, July 17th. They set a “buy” rating and a $385.00 target price for the company. Finally, Robert W. Baird increased their target price on shares of Axon Enterprise from $360.00 to $400.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 10th. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Axon Enterprise currently has an average rating of “Moderate Buy” and a consensus price target of $365.38.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.